Merck Cholesterol Pill
The FDA approved Merck's first-of-its-kind pill for high-risk cholesterol patients.
8
Articles
8
Sources
13%
Analysis & opinion
The reporting
The FDA approved Merck’s Lipfendra, making it the first once-daily oral PCSK9 inhibitor for lowering LDL cholesterol. The pill is authorized for people with hypercholesterolemia whose artery-clogging cholesterol remains high despite statins, the standard drugs used to lower heart-attack risk. PCSK9 inhibitors block a protein that limits the liver’s removal of LDL from the blood, a treatment approach previously available only as injections. In trials cited by Merck, Lipfendra cut LDL by nearly 60%, comparable to injectable PCSK9 drugs.
Analysis & opinion
The commentary is scattered.
weigh in — but each argues its own distinct claim, so no shared angle emerged. The other report the story straight.
Get tomorrow's edition
Every side, every morning — free in your inbox.


